staceywhite, Author at European Medical Journal - Page 60 of 194

Ovarian Hyperstimulation Syndrome Post-dilation and Evacuation of a Hydatidiform Mole: A Case Report

The present study reports a complete hydatidiform mole presenting with ovarian hyperstimulation syndrome after dilatation and evacuation…

Filling the Gap by Targeting the Gut: First Disease-Modifying Treatment Approved for IgA Nephropathy

Bengt Fellström, Uppsala University, Sweden, described the relationship between IgA nephropathy (IgAN) and gastrointestinal mucosal…

EAN 2023: Cutting edge diagnosis and management strategies in neuromuscular disease.

EAN 2023: Cutting edge diagnosis and management strategies in neuromuscular disease. This highly informative and thought-provoking…

Proteinuria as a Surrogate Endpoint for Disease Progression in IgA Nephropathy: Predicting Long-Term Treatment Effects of Sparsentan

IgA nephropathy (IgAN) is a rare, life-limiting disease for which there is significant unmet need. Until recently, drug development for…

EASL 2023 Interview: Irene Bargellini

Interview: Irene Bargellini – Following your medical degree, what sparked your interest in oncologic imaging and later liver imaging? The…

Enabling Timely Access to Medical Images and Information for Better Patient Treatment

Medical images have progressed from X-rays on film to digital capture. Sharing images to departments and hospitals remotely from the place…

Progressive Facial Hemiatrophy (Parry–Romberg Syndrome) Treated with Hyaluronic Acid Fillers

Parry–Romberg syndrome (PRS) is a rare neurocutaneous condition that can affect the skin, subcutaneous fat, muscle, and bone on one side…

RAS-ERK Pathway Genes Mutations in the Lesions from Various Tumour Loci in Multiple Myeloma

There is a trend towards higher frequency of high-risk cytogenetic aberrations in patients with NRAS gene mutations compared to patients with KRAS gene mutations. Read more.

Untangling Systemic Mastocytosis: An Update on Challenges in the Diagnosis and Treatment of Myeloid Neoplasms with Systemic Mastocytosis

The overarching message from the symposium was that diagnosis of SM-AHN is challenging, and SM is often missed in patients with a myeloid…

UBA1 Non-M41 Variants Are More Aggressive than UBA1 M41 Variants in Their Haematological Manifestations

The ongoing large-scale screen of non-M41 variants in patients suspected of HMs continues to detect both recurrent and novel non-M41 variants. The patients harbouring non-M41 variants are rare but may be more malignant.